Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Quidel Reports Third Quarter 2021 Financial Results: https://mms.businesswire.com/media/20191114005606/en/588971/5/Quidel_Horiz_Sml_Vector_CMYK.jpg
Quidel Reports Third Quarter 2021 Financial Results


Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the third

Chemed Corporation to Present at the 2021 Credit Suisse Virtual Healthcare Conference
Chemed Corporation to Present at the 2021 Credit Suisse Virtual Healthcare Conference


Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the Credit Suisse 30th Annual Virtual Healthcare Conference on Wednesday, November 10, 2021, at approximately

Sangamo Therapeutics Reports Recent Business and Clinical Highlights and Third Quarter 2021 Financial Results: https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg
Sangamo Therapeutics Reports Recent Business and Clinical Highlights and Third Quarter 2021 Financial Results


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported third quarter financial results and provided business and clinical highlights.



“We are delighted to share

Xencor to Present Data from the Phase 1 Study of Plamotamab in B-Cell Malignancies at the American Society of Hematology Annual Meeting: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Present Data from the Phase 1 Study of Plamotamab in B-Cell Malignancies at the American Society of Hematology Annual Meeting


Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today

Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease: https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg
Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, a

Navidea Biopharmaceuticals to Host Third Quarter 2021 Earnings Conference Call and Business Update: https://mms.businesswire.com/media/20191107006076/en/389794/5/navidea_cmyk.jpg
Navidea Biopharmaceuticals to Host Third Quarter 2021 Earnings Conference Call and Business Update


Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today

STAAR Surgical Reports Third Quarter Net Sales of $58.4 Million Up 24% Y/Y: https://mms.businesswire.com/media/20200413005098/en/683092/5/STAAR_Surgical_Logo_Primary_Lockup_%28Sunise_Teal%29.jpg
STAAR Surgical Reports Third Quarter Net Sales of $58.4 Million Up 24% Y/Y


STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the

Humana Specialty Pharmacy Wins National Patient Choice Award for Fourth Year in a Row: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Specialty Pharmacy Wins National Patient Choice Award for Fourth Year in a Row


Humana Specialty Pharmacy has received the MMIT Specialty Pharmacy Patient Choice Award in the PBM/Payer category for the fourth consecutive year. The award recognizes the highest quality in

Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced

Clovis Oncology Announces Third Quarter 2021 Operating Results: https://mms.businesswire.com/media/20191107005162/en/305545/5/Clovis_Logo_Process_Color.jpg
Clovis Oncology Announces Third Quarter 2021 Operating Results


Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2021, and provided an update on the Company’s clinical development programs and regulatory and

Charles River Laboratories Announces Third-Quarter 2021 Results: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories Announces Third-Quarter 2021 Results


Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2021. For the quarter, revenue was $895.9 million, an increase of 20.5% from $743.3

Owens & Minor Reports 3rd Quarter Financial Results: https://mms.businesswire.com/media/20211103005246/en/922805/5/O%26M_LogoTM_hi-res.jpg
Owens & Minor Reports 3rd Quarter Financial Results


Owens & Minor, Inc. (NYSE-OMI) today reported financial results for the third quarter of 2021, as summarized in the table below.



“I’m pleased that in the third quarter, we continued on our path

Xencor to Present at Upcoming Investor Conferences: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Present at Upcoming Investor Conferences


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced

Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results: https://mms.businesswire.com/media/20200817005658/en/810396/5/deciphera-logo-color-RGB-TM_.jpg
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results


Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the third quarter ended September 30, 2021 and provided a corporate update.



“In the third quarter, we made

PFIZER REPORTS THIRD-QUARTER 2021 RESULTShttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
PFIZER REPORTS THIRD-QUARTER 2021 RESULTS


Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2021 and raised 2021 guidance(4) for revenues and Adjusted diluted EPS(3) reflecting the net impact of its updated expectations

Premier, Inc. to Host Virtual Investor Day on November 17, 2021: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. to Host Virtual Investor Day on November 17, 2021


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that the company will host its 2021 Virtual Investor Day on Wednesday, November 17, 2021

Premier, Inc. Reports Fiscal-Year 2022 First-Quarter Results: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Reports Fiscal-Year 2022 First-Quarter Results


Premier, Inc. (NASDAQ: PINC) today reported financial results for the fiscal year 2022 first quarter ended September 30, 2021.



"We entered fiscal 2022 with strong momentum and are pleased with

Xencor to Host Third Quarter 2021 Financial Results Webcast and Conference Call on November 8, 2021: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Host Third Quarter 2021 Financial Results Webcast and Conference Call on November 8, 2021


Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today

Dexcom, Nick Jonas, Patti LaBelle and The Global Movement for Time in Range Invite the World to #SeeDiabetes This November
Dexcom, Nick Jonas, Patti LaBelle and The Global Movement for Time in Range Invite the World to #SeeDiabetes This November


Dexcom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, its nonprofit partners and members of the diabetes community are banding together to

Pipeline Health System, LLC Partners with Premier Inc.: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Pipeline Health System, LLC Partners with Premier Inc.


Pipeline Health System, LLC (“Pipeline Health”), an independent network of hospitals across California, Texas and Illinois, has selected Premier Inc. (NASDAQ: PINC), a leading technology-enabled

Agilent Announces New Ion Mobility LC/Q-TOF and Enhanced Solutions for Biotherapeutics at ASMS 2021:
Agilent Announces New Ion Mobility LC/Q-TOF and Enhanced Solutions for Biotherapeutics at ASMS 2021


Agilent Technologies Inc. (NYSE: A) announced today the new Agilent 6560C Ion Mobility LC/Q-TOF, enhancements to the VWorks automation software suite, and new AssayMAP large capacity cartridges

PerkinElmer Releases 2021 Corporate Social Responsibility Report: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24701/263px-PerkinElmer.svg.png
PerkinElmer Releases 2021 Corporate Social Responsibility Report


PerkinElmer, Inc. (NYSE: PKI), a global leader innovating for a healthier world, today released its 2021 Corporate Social Responsibility (CSR) Report, which summarizes the latest achievements of

Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Yearshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years


Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use the Pfizer-BioNTech COVID-19 Vaccine for

Agilent Companion Diagnostic Expands CE-IVD Mark in Europe to Include Triple-Negative Breast Cancer (TNBC)Pexels:
Agilent Companion Diagnostic Expands CE-IVD Mark in Europe to Include Triple-Negative Breast Cancer (TNBC)


Agilent Technologies Inc. (NYSE: A) today announced that its PD-L1 IHC 22C3 pharmDx assay is now labelled for use in TNBC in the European Union.



PD-L1 expression is a critical biomarker for

Sangamo Therapeutics Announces Third Quarter 2021 Conference Call and Webcast: https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg
Sangamo Therapeutics Announces Third Quarter 2021 Conference Call and Webcast


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its third quarter 2021 financial results on Thursday, November